Skip to main content

Table 3 Tolerability of baricitinib before and after temporary interruption based on adverse event terms reported by ≥ 2% of patients

From: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

n (%) First 4 weeks after initiating baricitinib (N = 318) First 4 weeks after restarting baricitinib (N = 318)
Patients with ≥ 1 TEAE 160 (50.3) 80 (25.2)
 Upper respiratory tract infection 15 (4.7) 5 (1.6)
 Headache 13 (4.1) 2 (0.6)
 Blood creatine phosphokinase increased 10 (3.1) 1 (0.3)
 Diarrhea 9 (2.8) 1 (0.3)
 Bronchitis 8 (2.5) 3 (0.9)
 Nausea 8 (2.5) 2 (0.6)
 Constipation 7 (2.2) 0
 Gastroenteritis 7 (2.2) 0
 Urinary tract infection 7 (2.2) 1 (0.3)
  1. TEAE treatment-emergent adverse event